Tag «WO 2018005328»

BICTEGRAVIR, NEW PATENT, WO 2018005328, CONCERT PHARMA

It’s only fair to share… BICTEGRAVIR, NEW PATENT, WO 2018005328, CONCERT PHARMA WO2018005328) DEUTERATED BICTEGRAVIR  CONCERT PHARMACEUTICALS, INC. TUNG, Roger, D.; (US) Concert CEO Roger Tung Novel deuterated forms of bictegravir is claimed.  Gilead Sciences is developing the integrase inhibitor bictegravir as an oral tablet for the treatment of HIV-1 infection. This invention relates to …